References
- Advani R., Saba H. I., Tallman M. S., Rowe J. M., Wiernik P. H., Ramek J., Dugan K., Lum B., Villena J., Davis E., Paietta E., Litchman M., Sikic B. I., Greenberg P. L. Treatment of refractory and relapsed acute myelogenenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Vaspodar). Blood 1999; 93: 787–795, [PUBMED], [INFOTRIEVE], [CSA]
- Aggarwal S., Tsuruo T., Gupta S. Altered expression and function of P‐glycoprotein (170 kDa), encoded by the MDR1 gene, in T cell subsets from aging humans. J. Clin. Immunol. 1997; 17: 448–454, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ambudkar S. V., Dey S., Hrycyna C. A., Ramachandra M., Pasta I., Gottesman M. M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 1999; 39: 361–398, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ambudkar S. V., Kimchi‐Sarfaty C., Sauna Z. E., Gottesman M. M. P‐glycoprotein: from genomics to mechanism. Oncogene 2003; 22: 7468–7485, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Andreef M., Konopleva M. Mechanism of drug resistance in AML. Cancer Treat. Res. 2002; 112: 237–262, [CSA]
- Ayrton A., Morgan P. Role of the transport proteins in drug absorption, distribution and excretion. Xenobiotica 2001; 31: 469–497, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Bakos E., Evers R., Sinko E., Varadi A., Borst P., Sarkadi B. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol. Pharmacol. 2000; 57: 760–768, [PUBMED], [INFOTRIEVE], [CSA]
- Beaumont K., Harper A., Smith D. A., Bennett J. The role of P‐glycoprotein in determining the oral absorption and clearance of the NK2 antagonist UK‐224,671. Eur. J. Pharm. Sci. 2000; 12: 41–50, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Benet L. Z., Cummins C. L. The drug efflux‐metabolism alliance: biochemical aspects. Adv. Drug Deliv. Rev. 2001; 50(suppl 1)S3–S11, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Bodo A., Bakos E., Szeri F., Varadi A., Sarkadi B. Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions. J. Biol. Chem. 2003; 278: 23529–23537, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Borst P., Elferink R. O. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 2002; 71: 537–592, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Borst P., Evers R., Kool M., Wijnholds J. The multidrug resistance protein family. Biochim. Biophys. Acta 1999; 1461: 347–357, [PUBMED], [INFOTRIEVE]
- Borst P., Evers R., Kool M., Wijnholds J. A family of drug transporters: the multidrug resistance‐associated proteins. J. Natl. Cancer Inst. 2000; 92: 1295–1302, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Bosch I., Dunussi‐Joannopoulos K., Wu R. L., Furlong S. T., Croop J. Phosphatidylcholine and phosphatidylethanolamine behave as substrates of the human MDR1 P‐glycoprotein. Biochem 1997; 36: 5685–5694, [CROSSREF]
- Bunting K. D. ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells 2002; 20: 11–20, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Burger H., Foekens J. A., Look M. P., Meijer van Gelder M. E., Klijn J. G., Wiemer E. A., Stoter G., Nooter K. RNA expression of breast cancer resistance protein, lung resistance‐related protein, multidrug resistance‐associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin. Cancer Res. 2003; 9: 827–836, [PUBMED], [INFOTRIEVE], [CSA]
- Cascorbi I., Gerloff T., Johne A., Meisel C., Hoffmeyer S., Eichelbaum M., Schwab M., Schaeffeler E., Brinkmann U., Roots J. Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. 2001; 69: 169–174, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Cascorbi I., Kroemer H. K., Siegmund W. Pharmacogenetics of P‐gp‐mediated drug transport. Nova Acta Leopold. 2003; 329: 93–100
- Castro A. F., Horton J. K., Vanoye C. G., Altenberg G. A. Mechanism of inhibition of P‐glycoprotein‐mediated drug transport by protein kinase C blockers. Biochem. Pharmacol. 1999; 58: 1723–1733, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Chan L. M.S., Lowes S., Hirst B. H. The ABC's of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur. J. Pharm. Sci. 2004; 21: 25–61, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Chen Z. S., Kawabe T., Ono M., Aoki S., Sumizawa T., Furukawa T., Uchiumi T., Wada M., Kuwano M., Akiyama S. I. Effect of multidrug resistance‐reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol. Pharmacol. 1999; 56: 1219–1228, [PUBMED], [INFOTRIEVE], [CSA]
- Choi C. H., Kang G., Min Y. D. Reversal of P‐glycoprotein‐mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng. Planta Med. 2003; 69: 235–240, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Chong A. S., Markham P. N., Gebel H. M., Bines S. D., Coon J. S. Diverse multidrug‐resistence‐modification agents inhibit cytolytic activity of natural killer cells. Cancer Immunol. Immunother. 1993; 36: 133–139, [PUBMED], [INFOTRIEVE]
- Choo E. F., Leake B., Wandel C., Imamura H., Wood A. J.J., Wilkinson G. R., Kim R. B. Pharmacological inhibition of P‐glycoprotein transport enhances the distribution of HIV‐1 protease inhibitors into brain and testes. Drug Metab. Disp. 2000; 28: 655–660, [CSA]
- Cole S. P.C., Deeley R. G. Multidrug resistance mediated by the ATP‐binding cassette transporter protein MRP. Bioessay 1998; 20: 931–940, [CSA]
- Conseil G., Perz‐Victoria J. M., Jault J. M., Gamarro F., Goffeau A., Hofmann J., Di Petro A. Protein kinase C effectors bind to multidrug ABC transporter and inhibit their activity. Biochem 2001; 40: 2564–2571, [CROSSREF]
- Dantzig A. H., Law K. L., Cao J., Starling J. J. Reversal of multidrug resistance by the P‐glycoprotein modulator, LY335979, from the bench to the clinic. Curr. Med. Chem. 2001; 8: 39–50, [PUBMED], [INFOTRIEVE]
- Dey S., Ramachandra M., Pastan I., Gottesman M. M., Ambudkar S. V. Evidence for two non‐identical drug‐interaction sites in the human P‐glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 10594–10599, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Dey S., Ramachandra M., Pastan I., Gottesman M. M., Ambudkar S. V. Photoaffinity labeling of human P‐glycoprotein: effect of modulator interaction and ATP hydrolysis on substrate binding. Methods Enzymol. 1998; 292: 318–328, [PUBMED], [INFOTRIEVE]
- Dong M., Ladavière L., Penin F., Deléage G., Baggetto L. G. Secondary structure of P‐glycoprotein investigated by circular dichroism and amino acid sequence analysis. Biochim. Biophys. Acta 1998; 1371: 317–334, [PUBMED], [INFOTRIEVE]
- Drescher S., Glaeser H., Murdter T., Hitzl M., Eichelbaum M., Fromm M. F. P‐glycoprotein‐mediated intestinal and biliary digoxin transport in humans. Clin. Pharmacol. Ther. 2003; 73: 223–231, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Durr D., Stieger B., Kullak‐Ublick G. A., Rentsch K. M., Steinert H. C., Meier P. J., Fattinger K. St. John's Wort induces intestinal P‐glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther. 2000; 68: 598–604, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Dussault I., Lin M., Hollister K., Wang E. H., Synold T. W., Forman B. M. Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J. Biol. Chem. 2001; 276: 33309–33312, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Evers R., de Haas M., Sparidans R., Beijnen J., Wielinga P. R., Lankelma J., Borst P. Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br. J. Cancer 2000; 83: 375–383, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Fellay J., Marzolini C., Back E. R., Buclin D. J., Chave T., Decosterd J. P., Furrer L. A., Opravil H., Pantaleo M., Retelska G., Ruiz D., Schinkel L., Vernazza A. H., Eap P., Telenti C. B. For the Swiss HIV cohort study. Response to antiretroviral treatment in HIV‐infected individuals with the allelic variants of the multidrug resistance transporter1: a pharmacogenetics study. Lancet 2002; 359: 30–36, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ferenci P., Zollner G., Trauner M. Hepatic transport systems. J. Gastroenterol. Hepatol. 2002; 17(suppl)S105–S112, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Fojo T., Bates S. Strategies for reversing drug resistance. Oncogene 2003; 22: 7512–7523, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Fracasso P. M., Brady M. F., Moore D. H., Walker J. L., Rose P. G., Letvak L., Grogan T. M., McGuire W. P. Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J. Clin. Oncol. 2001; 15: 2975–2982
- Fromm M. F. P‐glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int. J. Clin. Pharmacol. Ther. 2000; 38: 69–74, [PUBMED], [INFOTRIEVE]
- Fromm M. F. The influence of MDR1 polymorphisms on P‐glycoprotein expression and function in humans. Adv. Drug Deliv. Rev. 2002; 54: 1295–1310, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Fromm M. F., Kim R. B., Stein C. M., Wilkinson G. R., Roden D. M. Inhibition of P‐glycoprotein‐mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999; 99: 552–557, [PUBMED], [INFOTRIEVE], [CSA]
- Furuno T., Landi M. T., Ceroni E., Caporaso N., Bernucci I., Nappi G., Martignoni E., Schaeffeler E., Eichelbaum M., Schwab M., Zanger U. Expression polymorphism of the blood‐brain barrier component P‐glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 2002; 12: 529–534, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Garrigos M., Mir L. M., Orlowski S. Competitive and allosteric interaction in ligand binding to P‐glycoprotein ATPase: further experimental evidence for a multisite model. Eur. J. Biochem. 1997; 244: 664–673, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Gollapud S., Gupta S. Anti‐P‐glycoprotein antibody‐induced apoptosis of activated peripheral blood lymphocytes: a possible role of P‐glycoprotein in lymphocyte survival. J. Clin. Immunol. 2001; 21: 420–430, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Goto M., Masuda S., Saito H., Uemoto S., Kiuchi T., Tanaka K., Inui K. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living‐donor liver transplantation. Pharmacogenetics 2002; 12: 451–457, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Gottesman M. M., Pastan I., Ambudkar S. P‐glycoprotein and multidrug resistance. Curr. Opin. Genet. Dev. 1996; 6: 610–617, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Guo G. L., Lambert G., Negishi M., Ward J. M., Brewer H. B., Kliewer S. A., Gonzalez F. J., Sinal C. J. Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J. Biol. Chem. 2003; 278: 45062–45071, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hashimoto K., Uchiumi T., Konno T., Ebihara T., Nakamura T., Wada M., Sakisaka S., Maniwa F., Amachi T., Ueda K., Kuwano M. Trafficking and functional defects by mutations of the ATP‐binding domains in MRP2 in patients with Dubin–Johnson syndrome. Hepatology 2002; 36: 1236–1245, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hennessy M., Kelleher D., Spiers J. P., Barry M., Kavanagh P., Back D., Mulcahy F., Feely J. St. John's wort increases expression of P‐glycoprotein: implications for drug interactions. Br. J. Clin. Pharmacol. 2002; 53: 75–82, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Higgins C. F. ABC transporters: from microorganism to man. Ann. Rev. Cell Biol. 1992; 8: 67–113, [PUBMED], [INFOTRIEVE]
- Higgins C. F. ABC transporters: physiology, structure and mechanism—an overview. Res. Microbiol. 2001; 152: 205–210, [PUBMED], [INFOTRIEVE], [CSA]
- Hinoshita E., Uchiumi T., Taguchi K., Kinukawa N., Tsunecyoshi M., Machara Y., Sugimachi K., Kuwano M. Increased expression of an ATP‐binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinoma. Clin. Cancer Res. 2000; 6: 2401–2407, [PUBMED], [INFOTRIEVE], [CSA]
- Hipfner D. R., Deeley R. G., Cole S. P.C. Structural, mechanistic and clinical aspects of MRP 1. Biochim. Biophys. Acta 1999; 1461: 359–376, [PUBMED], [INFOTRIEVE]
- Hoffmeyer S., Burk O., von Richter O., Arnold H. P., Brockmöller J., Johne A., Cascorbi I., Gerloff T., Roots I., Eichelbaum M., Brinkmann U. Functional polymorphism of the human multidrug‐resistance gene: multiple sequence variations and correlation of one allele with P‐glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 3473–3478, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Homolya L., Varadi A., Sarkadi B. Multidrug resistance‐associated proteins: Export pumps for conjugates with glutathione, glucuronate or sulfate. Biofactors 2003; 17: 103–114, [PUBMED], [INFOTRIEVE], [CSA]
- Hou Y., Cui L., Riordan J. R., Chang X. Allosteric interactions between the two non‐equivalent nucleotide binding domains of multidrug resistance protein MRP1. J. Biol. Chem. 2000; 275: 20280–20287, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Huisman M. T., Smit J. W., Schinkel A. H. Significance of P‐glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000; 14: 237–242, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Huisman M. T., Smit J. W., Wiltshire H. R., Hoetelmans R. M., Beijnen J. H., Schinkel A. H. P‐glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol. Pharmacol. 2001; 59: 806–813, [PUBMED], [INFOTRIEVE], [CSA]
- Iida T., Kijima H., Urata Y., Goto S., Ihara Y., Oka M., Kohno S., Scanlon K. J., Kondo T. Hammerhead ribozyme against gamma‐glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down regulating both the glutahione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001; 8: 803–814, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ito S., Ieiri I., Tanabe M., Suzuki A., Higuchi S., Otubo K. Polymorphism of the ABC transporter genes. MDR1, MRP1, and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 2001; 11: 175–184, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Itoda M., Saito Y., Soyama A., Saeki M., Murayama N., Ishida S., Sai K., Nagano M., Suzuki H., Sugiyama Y., Ozawa S., Sawada J. Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5′‐untranslated region and exon 28. Drug Metab. Dispos. 2002; 30: 363–364, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Jager W., Gehring E., Hagenauer B., Aust S., Senderowicz A., Thalhammer T. The role of hepatic Mrp2 in the interaction of flavopiridol and bilirubin: impact on therapy. Int. J. Clin. Pharmacol. Ther. 2003; 41: 610–611, [PUBMED], [INFOTRIEVE]
- Jefferies P. R., Quistad G. B., Casida J. E. Dialkylquinonimines validated as in vivo metabolites of alachlor, acetochlor, and metolachlor herbicides in rats. Chem. Res. Toxicol. 1998; 11: 353–359, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Johnstone R. W., Cretney E., Smyth M. J. P‐glycoprotein protects leukemia cells against caspase‐dependent, but not caspase‐independent, cell death. Blood 1999; 93: 1075–1085, [PUBMED], [INFOTRIEVE], [CSA]
- Johnstone R. W., Ruefli A. A., Smyth M. J. Multiple physiological functions for multidrug transporter P‐glycoprotein?. Trends Biochem. Sci. 2000a; 25: 1–6, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Johnstone R. W., Ruefli A. A., Tainton K. M., Smyth M. J. A role for P‐glycoprotein in regulating cell death. Leuk. Lymphoma 2000b; 38: 1–11, [PUBMED], [INFOTRIEVE], [CSA]
- Jones P. M., George A. M. A new structural model for P‐glycoprotein. J. Membr. Biol. 1998; 166: 133–147, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Jones P. M., George A. M. Symmetry and structure in P‐glycoprotein and ABC transporters: what goes around comes around. Eur. J. Biochem. 2000; 267: 5298–5305, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kala S. V., Neely M. W., Kala G., Prater C. I., Atwood D. W., Rice J. S., Lieberman M. W. The MRP2/cMoat transporter and arsenic‐glutathione complex formation are required for biliary excretion of arsenic. J. Biol. Chem. 2000; 275: 33404–33408, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kalitsky‐Szirtes J., Shayeganpour A., Brocks D. R., Piquette‐Miller M. Suppression of drug‐metabolizing enzymes and efflux transporters in the intestine of endotoxin‐treated rats. Drug Metab. Dispos. 2004; 32: 20–27, [CSA], [CROSSREF]
- Karwattsky J., Lincoln M. C., Georges E. A mechanism for P‐glycoprotein‐mediated apoptosis as revealed by verapamil hypersensitivity. Biochem 2003; 42: 12163–12173, [CROSSREF]
- Kast H. R., Goodwin B., Tarr P. T., Jones S. A., Anisfeld A. M., Stoltz C. M., Tontonoz P., Kliewer S., Willson T. M., Edwards P. A. Regulation of multidrug resistance‐associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X‐activated receptor, and constitutive androstane receptor. J. Biol. Chem. 2002; 277: 2908–2915, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kaur P. Expression and characterization of DrrA and DrrB proteins of Streptomyces peucetius in Escherichia coli: DrrA is an ATP binding protein. J. Bacteriol. 1997; 179: 569–575, [PUBMED], [INFOTRIEVE]
- Keitel V., Kartenbeck J., Nies A. T., Spring H., Brom M., Keppler D. Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin–Johnson syndrome. Hepatology 2000; 32: 1317–1328, [PUBMED], [INFOTRIEVE]
- Keitel V., Nies A. T., Brom M., Hummel‐Eisenbeiss J., Spring H., Keppler D. A common Dubin–Johnson syndrome mutation impairs protein maturation and transport activity of MRP2 (ABCC2). Am. J. Physiol.: Gastrointest. Liver Physiol. 2003; 284: G165–G174
- Kerb R., Hoffmeyer S., Brinkmann U. ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2001; 2: 51–64, [PUBMED], [INFOTRIEVE], [CSA]
- Kim S. W., Kwon H. Y., Chi D. W., Shim J. H., Park J. D., Lee Y. H., Pyo S., Rhee D. K. Reversal of P‐glycoprotein‐mediated multidrug resistance by ginsenoside Rg (3). Biochem. Pharmacol. 2003; 65: 75–82, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- King M., Su W., Chang A., Zuckerman A., Pasternak G. W. Transport of opiods from the brain to the peripheral by P‐glycoprotein: peripheral actions of central drugs. Nature Neurosci. 2001; 4: 265–283, [CROSSREF]
- Klein I., Sarkadi B., Varadi A. An inventory of the human ABC proteins. Biochim. Biophys. Acta 1999; 1461: 237–267, [PUBMED], [INFOTRIEVE]
- Kobayashi N., Nishino K., Yamaguchi A. Novel macrolide‐specific ABC‐type efflux transporter in Escherichia coli. J. Bacteriol. 2001; 183: 5639–5644, [PUBMED], [INFOTRIEVE], [CROSSREF]
- König J., Nies A. T., Cui Y., Leier I., Keppler D. Conjugate export pumps of the multidrug protein (MRP) family: localization, substrate specifity, and MRP2‐mediated drug resistance. Biochim. Biophys. Acta 1999; 1461: 377–394
- Konings W. N., Poelarends G. J. Bacterial multidrug resistance mediated by a homologue of the human multidrug transporter P‐glycoprotein. IUBMB‐Life 2002; 53: 213–218
- Krishna R., Mayer L. D. Multidrug resistance (MDR) in Cancer. Mechanism, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 2000; 11: 265–283, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kruh G. D., Belinsky M. G. The MRP family of drug efflux pumps. Oncogene 2003; 22: 7537–7552, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kruh G. D., Zeng H., Rea P. A., Liu G., Chen Z. S., Lee K., Belinsky M. G. MRP sub‐family transporters and resistance to anticancer agents. J. Bioenerg. Biomembranes 2001; 33: 493–501, [CSA], [CROSSREF]
- Kullak‐Ublick G. A., Stieger B., Meier P. J. Enterohepatic salt transporters in normal physiology and liver disease. Gastroenterology 2004; 126: 322–342, [CSA], [CROSSREF]
- Kusuhara H., Suigiyama Y. Efflux transport system for drugs at blood‐brain barrier and blood‐cerebrospinal fluid barrier (Part 1). Drug Discov. Today 2001a; 6: 150–156, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kusuhara H., Suigiyama Y. Efflux transport system for drugs at blood‐brain barrier and blood‐cerebrospinal fluid barrier (Part 2). Drug Discov. Today 2001b; 6: 206–212, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kusuhara H., Suigiyama Y. Role of the tissue‐selective distribution and elimination of drugs: transporters in the liver, small intestine, brain, and kidney. J. Controlled release 2002; 78: 43–54, [CSA], [CROSSREF]
- Laffont C. M., Toutain P. L., Alvinerie M., Bousquet‐Melou A. Intestinal secretion is a major route for parent ivermectin elimination in the rat. Drug Metab. Dispos. 2002; 30: 626–630, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Lam F. C., Liu R., Lu P., Shapiro A. B., Renoir J. M., Sharom F. J., Reiner P. B. Beta‐amyloid efflux mediated by P‐glycoprotein. J. Neurochem. 2001; 76: 1121–1128, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Lankas G. R., Cartwright M. E., Umbenhauer D. P‐glycoprotein deficiency in a subpopulation of CF‐1 mice enhances avermectin‐induced neurotoxicity. Toxicol. Appl. Pharmacol. 1997; 143: 357–365, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Lankas G. R., Wise L. D., Cartwright M. E., Pippert T., Umbenhauer D. R. Placential P‐glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod. Toxicol. 1998; 12: 457–463, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Lavie Y., Fiucci G., Liscovitch M. Up‐regulation of caveolae and caveolar constituents in multidrug‐resistant cancer cells. J. Biol. Chem. 1998; 273: 32380–32383, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Lee Y. J., Kusuhara H., Sugiyama Y. Do multidrug resistance‐associated protein‐1 and‐2 play any role in the elimination of estradiol‐17beta‐glucuronide and 2,4‐dinitrophenyl‐S‐glutathione across the blood‐cerebrospinal fluid barrier?. J. Pharm. Sci. 2004; 93: 99–107, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Legare D., Richard D., Mukhopadhyay R., Stierhof Y. D., Rosen B. P., Haimeur A., Papadopoulou B., Quellette M. The Leishmania ATP‐bindig cassette protein PGPA is an intracellular metal‐thiol transporter. J. Biol. Chem. 2001; 276: 26301–26307, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Leonessa F., Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. Endocr. Relat. Cancer 2003; 10: 43–73, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Leslie E. M., Deeley R. G., Cole S. P.C. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 2001; 167: 3–23, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Liedert B., Materna V., Schadendorf D., Thomale J., Lage H. Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum‐DNA adducts and decreased G2‐arrest in melanoma cells resistant to cisplatin. J. Invest. Dermatol. 2003; 121: 172–176, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Lin J. H., Yamazaki M. Role of P‐glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet. 2003; 42: 59–98, [PUBMED], [INFOTRIEVE], [CSA]
- Lin J. H., Chiba M., Baillie T. A. Is the role of the small intestine in first pass metabolism overestimated?. Pharmacol. Rev. 1999; 51: 135–157, [PUBMED], [INFOTRIEVE], [CSA]
- Liscovitch M., Lavie Y. Multidrug resistance: a role for cholesterol efflux pathways?. Trends Biochem. Sci. 2000; 25: 530–534, [PUBMED], [INFOTRIEVE], [CSA]
- Liscovitch M., Lavie Y. Cancer multidrug resistance: a review of recent drug discovery research. Idrugs 2002; 5: 349–355, [PUBMED], [INFOTRIEVE], [CSA]
- Litman T., Druley T. E., Stein W. D., Bates S. E. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell. Mol. Life Sci. 2001; 58: 931–959, [PUBMED], [INFOTRIEVE], [CSA]
- Liu X. D., Liu G. Q. P‐glycoprotein regulated transport of glutamate at blood‐brain barrier. Acta Pharm. Sinica 2001; 22: 111–116, [CSA]
- Liu Y. Y., Han T. Y., Giuliano A. E., Cabot M. C. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J. 2001a; 15: 719–730, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Liu J., Chen H., Miller D. S., Saavedra J. E., Keefer L. K., Johnson D. R., Klaassen C. D., Waalkes M. P. Overexpression of glutathione S‐transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic. Mol. Pharmacol. 2001b; 60: 302–309, [PUBMED], [INFOTRIEVE], [CSA]
- Loo T. W., Clarke M. Determining the structure and mechanism of the human multidrug resistance P‐glycoprotein using cystein‐scanning mutagenesis and thiol modification techniques. Biochim. Biophys. Acta 1999; 1461: 315–325, [PUBMED], [INFOTRIEVE], [CSA]
- Lu L., Leonessa F., Clarke R., Wainer I. W. Competitive and allosteric interactions in ligand binding to P‐glycoprotein as observed on an immobilized P‐glycoprotein liquid stationary phase. Mol. Pharmacol. 2001; 59: 62–68, [PUBMED], [INFOTRIEVE], [CSA]
- Magnarin M., Morelli M., Rosati A., Bartoli F., Candussio L., Giraldi T., Decorti G. Induction of proteins involved in multidrug resistance (P‐glycoprotein, MRP1, MRP2, LRP) and of CYP 3A4 by rifampicin in LLC‐PK(1) cells. Eur. J. Pharmacol. 2004; 483: 19–28, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Markham P. N., Coon J. S., Chong A. S., Gebel H. M. Natural killer cell cytotoxicity and the multidrug resistance gene. Transplant. Proc. 1993; 25: 96–97, [PUBMED], [INFOTRIEVE], [CSA]
- Marroni M., Marchi N., Cucullo L., Abbott N. J., Signorelli K., Janigro D. Vascular and parenchymal mechanisms in multiple drug resistance: a lesson from human epilepsy. Curr. Drug Targets 2003; 4: 297–304, [PUBMED], [INFOTRIEVE], [CSA]
- Materna V., Lage H. Homozygous mutation Arg768Trp in the ABC‐transporter encoding gene MRP2/cMOAT/ABCC2 causes Dubin‐Johnson syndrome in a Caucasian patient. J. Hum. Genet. 2003; 48: 484–486, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Mayer U., Wagenaar E., Beijnen J. H., Smit J. W., Meijer D. K.F., Van Asperen J., Borst P., Schinkel A. H. Substantial excretion of digoxin via the intestinal mucosa and prevention of long‐term digoxin accumulation in the brain by the mdr1a P‐glycoprotein. Br. J. Pharmacol. 1996; 119: 1038–1044, [PUBMED], [INFOTRIEVE], [CSA]
- Mc Rae M. P., Brouwer K. L., Kashuba A. D. Cytokine regulation of P‐glycoprotein. Drug. Metab. Rev. 2003; 35: 19–33, [CSA], [CROSSREF]
- McGrath M. S., Rosenblum M. G., Philips M. R., Scheinberg D. A. Immunotoxin resistance in multidrug resistent cells. Cancer Res. 2003; 63: 72–79, [PUBMED], [INFOTRIEVE], [CSA]
- Mealey K. L., Bentjen S. A., Waiting D. K. Frequency of the mutant MDR1 allele associated with ivermectin sensitivity in a sample population of collies from the northwestern United States. Am. J. Vet. Res. 2002; 63: 479–481, [PUBMED], [INFOTRIEVE], [CSA]
- Miller D. S., Nobmann S. N., Gutmann H., Toeroek M., Drewe J., Fricker G. Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Mol. Pharmacol. 2000; 58: 1357–1367, [PUBMED], [INFOTRIEVE], [CSA]
- Mor‐Cohen R., Zivelin A., Rosenberg N., Shani M., Muallem S., Seligsohn U. Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin–Johnson syndrome. J. Biol. Chem. 2001; 276: 36923–36930, [CSA], [CROSSREF]
- Moriya Y., Nakamura T., Horinouchi M., Sakaeda T., Tamura T., Aoyama N., Shirakawa T., Gotoh A., Fujimoto S., Matsuo M., Kasuga M., Okomura K. Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA's expression level in duodenal enterocytes of healthy Japanese subjects. Biol. Pharm. Bull. 2002; 25: 1356–1359, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Mottino A. D., Hoffman T., Jennes L., Cao J., Vore M. Expression and localization of multidrug resistant protein mrp2 in rat small intestine. Am. J. Physiol.: Gasterointest. Liver Physiol. 2001; 280: G1261–G1273, [CSA]
- Müller M. Transcriptional control of hepatocanalicular transporter gene expression. Semin. Liver Dis. 2000; 20: 323–337, [CSA], [CROSSREF]
- Müller M. 48 human ATP‐binding cassettes transporters. January 2004, Internet site http://www.nutrigene.4t.com/humanabc.htm, [CSA]
- National Institutes of Health. P‐glycoprotein antagonist, tariquidar, in combination with doxorubicin (Adriamycin), vinorelbine (Navelbine), or docetaxel to treat children with solid tumors. January, 2004a, Internet site http://www. clinicaltrials.gov./ct/action, [CSA]
- National Institutes of Health. Tariquidar and docetaxel to treat patients with lung, ovarian, and cervical tumors. January, 2004b, Internet site http://www. clinicaltrials. gov./ct/ action, [CSA]
- National Institutes of Health. Surgery plus chemotherapy (doxorubicin, vincristine and etoposide), mitotane, and triquidar to treat adrenocortical cancer. January, 2004c, Internet site http://www. clinicaltrials.gov./ct/action, [CSA]
- Nies A. T., Konig M., Pfannschmidt M., Klar E., Hofmann W. J., Keppler D. Expression of the multidrug resistance protein MRP2 and MRP3 in human hepatocellular carcinoma. Int. J. Cancer 2001; 94: 492–499, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Nobmann S., Bauer B., Fricker G. Ivermectin excretion by isolated functionally intact brain endothelial capillaries. Br. J. Pharmacol. 2001; 132: 722–728, [PUBMED], [INFOTRIEVE], [CSA]
- Ogawa K., Suzuki H., Hirohashi T., Ishikawa T. , Meier P. J., Hirose K., Akizawa T., Yoshioka M., Sugiyama Y. Characterization of inducible nature of MRP3 in rat liver. Am. J. Physiol. 2000; 278: G438–G446, [CSA]
- Ohishi Y., Oda Y., Uchiumi T., Kobayashi H., Hirakawa T., Miyamoto S., Kinukawa N., Nakano H., Kuwano M., Tsuneyoshi M. ATP‐binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. Clin. Cancer Res. 2002; 8: 3767–3775, [PUBMED], [INFOTRIEVE], [CSA]
- Pauli‐Magnus C., Mürdter T., Godel A., Mettang T., Eichelbaum M., Klotz U., Fromm M. F. P‐glycoprotein‐mediated transport of digitoxin, alpha‐methyldigoxin and beta‐acetyldigoxin. Naunyn Schmiedberg's Arch. Pharmacol. 2001; 363: 337–343, [CSA], [CROSSREF]
- Paulusma C. C., Kool M., Bosma P. J., Scheffer G. L., ter Borg F., Scheper R. J., Tytgat G. N., Borst P., Baas F., Oude Elferink R. P. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin–Johnson syndrome. Hepatology 1997; 25: 1539–1542, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Payen L., Sparfel A., Courtois L., Vernhet A., Guillouzo A., Fardel O. The drug efflux pump MRP2: Regulation of expression in physiopathological situations and by endogenous and exogenous compounds. Cell Biol. Toxicol. 2002; 18: 221–233, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Pendse S., Sayegh M. H., Frank M. H. P‐glycoprotein—a novel therapeutic target for immunomodulation in clinical transplantation and autoimmunity?. Curr. Drug Targets 2003; 4: 469–476, [PUBMED], [INFOTRIEVE], [CSA]
- Pippert T. R., Umbenhauer D. R. The subpopulation of CF‐1 mice deficient in P‐glycoprotein contains a murine retroviral insertion in the mdr1a gene. J. Biochem. Mol. Toxicol. 2001; 15: 83–89, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ramachandra M., Ambudkar S. V., Chen D., Hrycyna C. A., Dey S., Gottesman M. M., Pastan I. Human P‐glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. Biochem 1998; 37: 5010–5019, [CSA], [CROSSREF]
- Rea P. A., Li Z., Lu Y., Drozdowicz Y. M., Martinoia E. From vacuolar GS‐X pumps to multispecific ABC transporters. Annu. Rev. Plant Physiol. Plant Mol. Biol. 1998; 49: 727–760, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Romsicki Y., Sharom F. J. Phospholipid flippase activity of the reconstituted P‐glycoprotein multidrug transporter. Biochem 2001; 40: 6934–6947, [CSA]
- Rosenberg M. F., Callaghan R., Ford R. F., Higgins C. F. Structure of the multidrug resistance P‐glycoprotein to 2.5 nm resolution by electron micoscopy and image analysis. J. Biol. Chem. 1997; 272: 10685–10694, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Roulet A., Puel O., Gesta S., Lepage J. F., Drag M., Soll M., Alvinerie M., Pineau T. MDR1‐deficient genotype in Collie dogs hypersensitive to the P‐glycoprotein substrate ivermectin. Eur. J. Pharmacol. 2003; 24: 85–91, [CSA], [CROSSREF]
- Ruefli A. A., Smyth M. J., Johnstone R. W. HMBA induces activation of a caspase‐independent cell death pathway to overcome P‐glycoprotein‐mediated multidrug resistance. Blood 2000; 95: 2378–2385, [PUBMED], [INFOTRIEVE], [CSA]
- Ruefli A. A., Tainton K. M., Darcy P. K., Smyth M. J., Johnstone R. W. P‐glycoprotein inhibits caspase‐8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ. 2002; 9: 1266–1272, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Russel F. G.M., Masereeuw R., van Aubel R. A.M.H. Molecular aspects of renal anionic drug transport. Annu. Rev. Physiol. 2002; 64: 563–594, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Saito T., Zhang Z. J., Ohutsubo T., Noda I., Shibamori Y., Yamamoto T., Saito H. Homozygous disruption of the mdr1a P‐glycoprotein gene affects blood‐nerve barrier function in mice administered with neurotoxic drugs. Acta Otolaryngol. 2001; 121: 735–742, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Schinkel A. H., Jonker J. W. Mammalian drug efflux transporters of the ATP binding cassete (ABC) family: an overview. Adv. Drug Deliv. Rev. 2003; 55: 3–29, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Schinkel A. H., Smit J. J., van Tellingen O., Beijnen J. H., Wagenaar E., van Deemter L., Mol C. A., van der Valk E. C., Robanus‐Maandag E. C., te Tiele H. P. Disruption of the mouse MDR1a P‐glycoprotein gene leads to a deficiency in the blood brain barrier and to increased sensitivity to drugs. Cell 1994; 77: 491–502, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Schinkel A. H., Mayer U., Wagenaar E., Mol C. A., van Deemter L., Smit J. J., van der Valk M. A., Voordouw A. C., Spits H., van Tellingen O., Zijlmans J. M., Fibbe W. E., Borst P. Normal viability and altered pharmacokinetics in mice lacking mdr1‐type (drug transporting) P‐glycoproteins. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 4028–4033, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Schwab M., Eichelbaum M., Fromm M. F. Genetic polymorphism of the human MDR1 drug transporter. Annu. Rev. Pharmacol. Toxicol. 2003; 43: 285–307, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Seelig A. How does P‐glycoprotein recognize its substrates?. Int. J. Clin. Pharmakol. Ther. 1998; 36: 50–54, [CSA]
- Seelig A., Blatter X. L., Wohnsland F. Substrate recognition by P‐glycoprotein and the multidrug resistance‐associated protein MRP1: a comparison. Int. J. Clin. Pharmacol. Ther. 2000; 38: 111–121, [PUBMED], [INFOTRIEVE], [CSA]
- Shabbits J. A., Mayer L. D. P‐glycoprotein modulates ceramide‐mediated sensitivity of human breast cancer cells to tubulin‐binding anticancer drugs. Mol. Cancer Ther. 2002; 1: 205–213, [PUBMED], [INFOTRIEVE], [CSA]
- Sharma R., Awasthi Y. C., Yang Y., Sharma A., Singhal S. S., Awasthi S. Energy dependent transport of xenobiotics and its relevance to multidrug resistance. Curr. Cancer Drug Target 2003; 3: 89–107, [CSA]
- Sharom F. J., Liu R., Romsicki Y., Lu P. Insights into the structure and substrates interactions of the P‐glycoprotein multidrug transporter from spectroscopic studies. Biochim. Biophys. Acta 1999; 1461: 327–345, [PUBMED], [INFOTRIEVE], [CSA]
- Siddiqui A., Kerb R., Weale M. E., Brinkmann U., Smith A., Goldstein D. B., Wood N. W., Sissodiva S. M. Association of multidrug resistance in epilepsy with a polymorphism in the drug‐transporter gene ABCB1. N. Engl. J. Med. 2003; 348: 1442–1448, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Sietsma H., Veldman R. J., Kok J. W. The involment of sphingolipids in multidrug resistance. J. Membr. Biol. 2001; 181: 153–162, [PUBMED], [INFOTRIEVE], [CSA]
- Smit J. W., Huisman M. T., van Tellingen O., Wiltshire H. R., Schinkel A. H. Absence or pharmacological blocking of placental P‐glycoprotein profoundly increases fetal drug exposure. J. Clin. Invest. 1999; 104: 1441–1447, [PUBMED], [INFOTRIEVE], [CSA]
- Soini Y., Jarvinen K., Kaarteenaho‐Wiik R., Kinnula V. The expression of P‐glycoprotein and multidrug resistance proteins1 and 2 (MRP1 and MRP2) in human malignat mesothelioma. Ann. Oncol. 2001; 12: 1239–1245, [PUBMED], [INFOTRIEVE], [CSA]
- Sparreboom A., van Asperen J., Mayer U., Schinkel A. H., Smit J. W., Meijer D. K.F., Borst P., Nooijen W. J., Beijnen J. H., van Tellingen O. Limited oral bioavailability and active epithelial excretion of paxlitaxel (Taxol) caused by P‐glycoprotein in the intestine. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 2031–2035, [PUBMED], [INFOTRIEVE], [CSA]
- Sparreboom A., Danesi R., Ando Y., Chan J., Figg W. D. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist. Updat. 2003; 6: 71–84, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- St. Pierre M. V., Serrano M. A., Macias R. I., Dubs U., Hoechli M., Lauper U., Meier P. J., Marin J. J. Expression of members of the multidrug resistance protein family in human term placenta. Am. J. Physiol., Regul. Integr. Comp. Physiol. 2000; 279: R1495–R1503, [CSA]
- St. Pierre M. V., Ugele B., Gambling L., Shiverick K. T. Mechanisms of drug transfer across the human placenta‐a workshop report. Placenta 2002; 23(suppl A)S159–S164, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Steinbach D., Lengemann J., Voigt A., Hermann J., Zintl F., Sauerbrey A. Response to chemotherapy and expression of the genes encoding the multidrug resistance‐associated proteins MRP2, MRP3, MRP4, MRP5, and SMRP in childhood acute myeloid leukemia. Clin. Cancer Res. 2003; 9: 1083–1086, [PUBMED], [INFOTRIEVE], [CSA]
- Stephens R. H., Neill C. A.O., Warhurst A., Carlson G. L., Rowland M., Warhus G. Kinetic profile of P‐glycoprotein‐mediated drug efflux in rat and human intestinal epithelia. J. Pharmacol. Exp. Ther. 2001; 296: 584–591, [PUBMED], [INFOTRIEVE], [CSA]
- Stewart A., Steiner J., Mellows G., Laguda B., Norris D., Bevan P. Phase I trail of XR9576 in healty volunteers demonstrates modulation of P‐glycoprotein in CD56 + lymphocytes after oral and intravenous administration. Clin. Cancer Res. 2000; 6: 4186–4191, [PUBMED], [INFOTRIEVE], [CSA]
- Stockel B., Konig J., Nies A. T., Cui Y., Bom M., Keppler D. Characterization of the 5′‐flanking region of the human multidrug resistance protein 2 (MRP2) gene and its regulation in comparison with the multidrug resitance protein 3 (MRP3) gene. Eur. J. Biochem. 2000; 267: 1347–1358, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Suzuki H., Sugiyama Y. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv. Drug Deliv. Rev. 2002; 54: 1311–1331, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Tamai I., Tsui A. Transporter‐mediated permeation of drugs across the blood‐brain barrier. J. Pharm. Sci. 2000; 89: 1371–1388, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Tammur J., Prades C., Arnould I., Rzhetsky A., Hutchinson A., Adachi M., Schuetz J., Swoboda K., Ptacek L., Rosier M., Dean M., Allikmets R. Two new genes from human ATP‐binding cassette transporter superfamily ABC c11 and ABC c12, tandemly duplicated on chromosome 16q12. Genes 2001; 273: 89–96, [CSA]
- Tanigawara Y. Role of P‐glycoprotein in drug disposition. Ther. Drug Monit. 2000; 22: 137–140, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Tate G., Li M., Suzuki T., Mitsuya T. A new mutation of the ATP‐binding cassette, sub‐family C, member 2 (ABCC2) gene in a Japanese patient with Dubin–Johnson syndrome. Genes Genet. Syst. 2002; 77: 117–121, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Teodori E., Dei S., Scapecchi S., Gualtieri F. The medical chemistry of multidrug resistance (MDR) reversing drugs. Farmaco 2002; 57: 385–415, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Toh S., Wada M., Uchiumi T., Inokuchi A., Makino Y., Horie Y., Adachi Y., Sakisaka S., Kuwano M. Genomic structure of the canicular multispecific organic anion transporter gene (MRP2/cMOAT) and mutations in the ATP‐binding cassette region in Dubin–Johnson syndrome. Am. J. Hum. Genet. 1999; 64: 739–746, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Trauner M., Boyer J. L. Bile salt transporters: molecular characterization, function, and regulation. Physiol. Rev. 2003; 83: 633–671, [PUBMED], [INFOTRIEVE], [CSA]
- Trauner M., Arrese M., Soroka C., Ananthanarayanan M., Koeppel T. A., Schlosser S. F., Suchy F. J., Keppler D., Boyer J. L. The rat canicular conjugate export pump (mrp2) is down regulated in intrahepatic and obstructive cholestasis. Gastroenterology 1997; 113: 255–264, [PUBMED], [INFOTRIEVE], [CSA]
- Treichel R. S., Bunuan M., Hahn N., Wee K. Altered conjugate formation and altered apoptosis of multidrug‐resistant human leukemia cell line affects susceptibility to killing by activated natural killer cells. Int. J. Cancer 2004; 108: 78–85, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Tsujii H., Konig J., Rost D., Stockel B., Leuschner U., Keppler D. Exon‐intron organization of the multidrug‐resistance protein 2 (MRP2) gene mutated in Dubin–Johnson syndrome. Gastroenterology 1999; 117: 653–660, [PUBMED], [INFOTRIEVE], [CSA]
- Usigome F., Takanaga H., Matsuo H., Yanai S., Tsukimori K., Nakano H., Uchiumi T., Nakamura T., Kuwano M., Ohtani H., Sawada Y. Human placental transport of vinblastine, vincrisitine, digoxin, and progesterone: contribution of P‐glycoprotein. Eur. J. Pharmacol. 2000; 408: 1–10, [CSA], [CROSSREF]
- Van Asperen J., Van Tellingen O., Beijnen J. H. The role of MDR1A P‐glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastin in mice. Drug Metab. Dispos. 2000; 28: 264–267, [PUBMED], [INFOTRIEVE], [CSA]
- Van Aubel R. A., Koenderink J. B., Peters J. G., Van Os C. H., Russel F. G. Mechanisms and interaction of vinblastine and reduced glutathione transport in membrane vesicles by the rabbit multidrug resistance protein Mrp2 expressed in insect cells. Mol. Pharmacol. 1999; 56: 714–719, [PUBMED], [INFOTRIEVE], [CSA]
- Van Helvoort A., Smith A. J., Sprong H., Fritzsche I., Schinkel A. H., Borst P., van Meer G. MDR1 P‐glycoprotein is a lipid translocase of broad specifity, while MDR3 P‐glycoprotein specifically translocates phosphatidylcholine. Cell 1996; 87: 507–515, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Van Veen H. W., Konings W. N. A bacterial antibiotic resistance gene that complements the human multidrug‐resistance P‐glycoprotein gene. Nature 1998; 391: 291–295, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Van Veen H. W., Venema K., Bolhuis H., Oussenko I., Kok J., Poolman B., Driessen A. J., Konings W. N. Multidrug resistance mediated by a bacterial homolog of the multidrug transport MDR 1. Proc. Natl. Acad. Sci. U. S. A. 1996; 93: 10668–10672, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Van Zuylen L., Nooter K., Sparreboom A., Verweij J. Development of multidrug‐resistance convertors: sense or nonsense?. Invest. New Drugs 2000; 18: 205–220, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Van Zuylen L., Sparreboom A., Nooter K., Eskens F. A., Brouwer E., Bol C. J., de Vries R., Palmer P. A., Verweij J. Disposition of docetaxel in the presence of P‐glycoprotein inhibition by intravenous administration of R101933. Eur. J. Cancer 2002; 38: 1090–1099, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Varadi A., Szakacs G., Bakos E., Sarkadi B. P‐glycoprotein and the mechanism of multidrug resistance. Novartis Found. Symp. 2002; 243: 54–65, [PUBMED], [INFOTRIEVE], [CSA]
- Vernhet L., Seite M. P., Allain N., Guillouzo A., Fardel O. Arsenic induces expression of the multidrug resistance‐associated protein 2 (MRP2) gene in primary rat and human hepatocytes. J. Pharmacol. Exp. Ther. 2001; 298: 234–239, [PUBMED], [INFOTRIEVE], [CSA]
- Vernhet L., Allain N., Le Vee M., Morel F., Guillouzo A., Fardel O. Blockage of multidrug resistance‐associated proteins potentiates the inhibitory effects of arsenic trioxide on CYP1A1 induction by polycyclic aromatic hydrocarbons. J. Pharmacol. Exp. Ther. 2003; 304: 145–155, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Vogelgesang S., Cascorbi I., Schroeder E., Pahnke J., Kroemer H. K., Siegmund W., Kunert‐Keil C., Walker L. C., Warzok R. W. Deposition of Alzheimer's beta‐amyloid is inversely correlated with P‐glycoprotein expression in the brains of elderly non‐demented humans. Pharmacogenetics 2002; 12: 535–541, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wada M., Toh S., Taniguchi K., Nakamura T., Uchiumi T., Kohno K., Yoshida I., Kimura A., Sakisaka S., Adachi Y., Kuwano M. Mutations in the canalicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin–Johnson syndrome. Biochem. Biophys. Res Commun. 1998; 253: 454–457, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wakusawa S., Machida I., Suzuki S., Hayashi H., Yano M., Yoshioka K. Identification of a novel 2026G → C mutation of the MRP2 gene in a Japanese patient with Dubin–Johnson syndrome. J. Hum. Genet. 2003; 48: 425–429, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Walker J., Saraste M., Runswick M. J., Gay N. J. Distantly related sequences in the α‐ and β‐subunits of ATP synthase, myosin, kinases, and other ATP‐requiring enzymes and a common nucleotide binding fold. EMBO J. 1982; 1: 945–951, [PUBMED], [INFOTRIEVE], [CSA]
- Wang E. J., Johnson W. W. The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2. Chemotherapy 2003; 49: 303–308, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Weiss J., Dormann S. M., Martin‐Facklam M., Kerpen C. J., Ketabi‐Kiyanvash N., Haefeli W. E. Inhibition of P‐glycoprotein by newer antidepressants. J. Pharmacol. Exp. Ther. 2003; 305: 197–204, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Westphal K., Weinbrenner A., Giessmann T., Stuhr M., Franke G., Zschiesche M., Oertel R., Terhaag B., Kroemer H. K., Siegmund W. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involment of intestinal P‐glycoprotein. Clin. Phamacol. Ther. 2000a; 68: 6–12, [CSA], [CROSSREF]
- Westphal K., Weinbrenner A., Zschiesche M., Franke G., Knoke M., Oertel R., von Richter O., Warzok R., Hachenberg T., Kaumann H. M., Schrenk D., Terhaag B., Kroemer H. K., Siegmund W. Induction of P‐glycoprotein by rifampicin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin. Pharmacol. Ther. 2000b; 68: 345–355, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wielandt A. M., Vollrath V., Manzano M., Miranda S., Accatino L., Chianale J. Induction of the multispecific organic anion transporter (cMoat/mrp2) gene and biliary glutathione secretion by the herbicide 2,4,5‐trichlorophenoxyacetic acid in the mouse liver. Biochem. J. 1999; 341: 105–111, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wortelboer H. M., Usta M., van der Velde A. E., Boersma M. G., Spenkelink B., van Zanden J. J., Rietjens I. M., van Bladeren P. J., Cnubben N. H. Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin. Chem. Res.Toxicol. 2003; 16: 1642–1651, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Yasuda K., Lan L. B., Sanglard D., Furuya K., Schuetz J. D., Schuetz E. G. Interaction of Cytochrome P4503A inhibitors with P‐glycoprotein. J. Pharmacol. Ther. 2002; 303: 323–332, [CSA], [CROSSREF]
- Young J., Holland I. B. ABC transporters: bacterial exporters—revised five years on. Biochim. Biophys. Acta 1999; 1461: 177–200, [PUBMED], [INFOTRIEVE], [CSA]
- Zollner G., Fickert P., Zenz R., Fuchsbichler A., Stumptner C., Kenner L., Ferenci P., Stauber R. E., Krejs G. J., Denk H., Zatloukal K., Trauner M. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 2001; 33: 633–646, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Zollner G., Fickert P., Silbert D., Fuchsbichler A., Marschall H. U., Zatloukal K., Denk H., Trauner M. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J. Hepatol. 2003; 38: 717–727, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]